Clinical Trial Finder

Inclusion Criteria:

• - Patients with complete surgical resection of histologically confirmed AJCC (8th edition) clinical stage III (IIIA, IIIB, IIIC, IIID) melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib has been made before entering the study.

• - V600E/K mutation-positive cutaneous melanoma.

• - Adjuvant treatment with combination therapy of Dabrafenib (Tafinlar®) and Trametinib (Mekinist®) as indicated in the SmPC and by prescription, that has been started before inclusion of the patient into the study; - ≥ 18 years of age.

• - Written informed consent signed.

Exclusion Criteria:

• - Lack of basic demographic (gender, age, age at diagnosis) and staging data (Stage at diagnosis; Breslow index; Clark level; BRAF mutation; BRAF test date; Surgery date).

The prospective registration of completely resected high-risk stage III melanoma patients treated with dabrafenib and trametinib in the adjuvant setting will be based on collaboration with 8 centers of excellence on melanoma patients treatment, according to their expertise and experience. Patients will be recruited from participating centers in the routine setting. This will be done only if the decision about starting treatment with dabrafenib and trametinib has already been made. All patients that comply with the inclusion criteria and that start treatment with dabrafenib+ trametinib during the recruitment period will be considered to participate in the study, at investigator discretion. Health related quality of life will be assessed by FACT-M and EQ-5D-3L questionnaire after treatment initiation in a quarterly base, according to clinical practice, including the first visit after treatment completion.

Arms

Interventions